Jun 15, 2021 8:00 am EDT Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
May 25, 2021 9:03 am EDT Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
Apr 1, 2021 7:30 am EDT Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
Mar 23, 2021 7:30 am EDT Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
Mar 18, 2021 8:00 am EDT Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25
Mar 17, 2021 8:00 am EDT Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis